Stryker's Record $25.1B Revenue Fuels Valuation Debate: Is the MedTech Giant Still Undervalued?
Stryker Corporation's latest earnings report, driven by its MedSurg, Neurotechnology divisions and the Mako surgical robot, has reignited investor debate. With shares near $370 and a bullish fair value estimate of $427, analysts are weighing robust growth against a premium valuation.